Lexicon Pharmaceuticals Inc banner

Lexicon Pharmaceuticals Inc
NASDAQ:LXRX

Watchlist Manager
Lexicon Pharmaceuticals Inc Logo
Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
Watchlist
Price: 2.335 USD -0.21% Market Closed
Market Cap: $1B

Intrinsic Value

The intrinsic value for Lexicon Pharmaceuticals Inc (LXRX) under the Base Case is 1.649 USD. Compared with the current market price of 2.335 USD, the stock appears Overvalued by 29% .

Intrinsic value calculated using Multiples
$1.649
Other reference points

Do our valuations actually work? See backtest results .

LXRX Intrinsic Value
$1.649
Overvaluation 29%
Intrinsic Value
Price $2.335
Monitor LXRX
Get notified when the price drops
Track Buy Zone
20% below Intrinsic Value $1.32
Get notified when the price drops into your buy zone
Current Price $2.34
Intrinsic Value $1.65
Margin of Safety 20% $1.32
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Valuation History
Ask AI Assistant
What other research platforms think about LXRX?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is LXRX valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Lexicon Pharmaceuticals Inc.

Explain Valuation
Alternatives to LXRX

Wall St Price Targets

Capital Returns

Competitive Landscape

Ownership

LXRX Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one LXRX stock?

The intrinsic value for Lexicon Pharmaceuticals Inc (LXRX) under the Base Case is 1.649 USD.

Is LXRX stock undervalued or overvalued?

Compared with the current market price of 2.335 USD, the stock appears Overvalued by 29% .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett